Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurodevelopmental Disorders | 3 | 2021 | 475 | 1.150 |
Why?
|
| Neurological Rehabilitation | 1 | 2024 | 6 | 0.920 |
Why?
|
| Recovery of Function | 2 | 2017 | 437 | 0.850 |
Why?
|
| Craniocerebral Trauma | 3 | 2022 | 125 | 0.740 |
Why?
|
| Encephalitis | 2 | 2023 | 108 | 0.720 |
Why?
|
| Child Abuse | 3 | 2022 | 195 | 0.670 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2019 | 101 | 0.660 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2019 | 9 | 0.660 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 18 | 0.650 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 30 | 0.640 |
Why?
|
| Population Surveillance | 1 | 2021 | 383 | 0.610 |
Why?
|
| Autoantibodies | 2 | 2023 | 422 | 0.570 |
Why?
|
| Hashimoto Disease | 1 | 2017 | 21 | 0.570 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 370 | 0.560 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 50 | 0.540 |
Why?
|
| Astrocytes | 1 | 2019 | 250 | 0.530 |
Why?
|
| Athletic Injuries | 1 | 2017 | 57 | 0.530 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 360 | 0.520 |
Why?
|
| Status Epilepticus | 1 | 2017 | 139 | 0.510 |
Why?
|
| Brain Injuries | 2 | 2024 | 734 | 0.470 |
Why?
|
| Brain Concussion | 1 | 2017 | 225 | 0.450 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 94 | 0.420 |
Why?
|
| Child | 16 | 2024 | 24208 | 0.350 |
Why?
|
| Injury Severity Score | 3 | 2017 | 219 | 0.350 |
Why?
|
| Brain Diseases | 2 | 2023 | 294 | 0.340 |
Why?
|
| Critical Illness | 2 | 2024 | 595 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 3518 | 0.300 |
Why?
|
| Fever | 2 | 2022 | 296 | 0.290 |
Why?
|
| Neurocognitive Disorders | 2 | 2018 | 67 | 0.290 |
Why?
|
| Neuroimaging | 4 | 2022 | 332 | 0.240 |
Why?
|
| Humans | 26 | 2024 | 123199 | 0.230 |
Why?
|
| Nerve Net | 2 | 2017 | 236 | 0.220 |
Why?
|
| Epilepsy | 2 | 2022 | 859 | 0.210 |
Why?
|
| Ascaridoidea | 1 | 2022 | 6 | 0.210 |
Why?
|
| Ascaridida Infections | 1 | 2022 | 6 | 0.210 |
Why?
|
| Diffuse Axonal Injury | 1 | 2022 | 10 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 154 | 0.200 |
Why?
|
| Spinal Injuries | 1 | 2022 | 29 | 0.200 |
Why?
|
| Meningitis | 1 | 2022 | 99 | 0.200 |
Why?
|
| Adolescent | 8 | 2022 | 19086 | 0.190 |
Why?
|
| Exanthema | 1 | 2022 | 68 | 0.180 |
Why?
|
| Language Development Disorders | 1 | 2022 | 173 | 0.180 |
Why?
|
| Nervous System | 1 | 2021 | 128 | 0.180 |
Why?
|
| Patient Discharge | 2 | 2022 | 488 | 0.180 |
Why?
|
| White Matter | 1 | 2022 | 181 | 0.180 |
Why?
|
| Cartilage Diseases | 1 | 2020 | 13 | 0.180 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 26 | 0.170 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2020 | 11 | 0.170 |
Why?
|
| Infant | 7 | 2022 | 12323 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 171 | 0.170 |
Why?
|
| Disease Progression | 3 | 2022 | 2027 | 0.170 |
Why?
|
| Embolism | 1 | 2020 | 49 | 0.170 |
Why?
|
| Male | 13 | 2023 | 60021 | 0.170 |
Why?
|
| Hematoma, Subdural | 1 | 2019 | 20 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 171 | 0.170 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2019 | 18 | 0.170 |
Why?
|
| Child, Preschool | 6 | 2022 | 13862 | 0.160 |
Why?
|
| Botulism | 1 | 2018 | 9 | 0.160 |
Why?
|
| Brain Waves | 1 | 2019 | 46 | 0.160 |
Why?
|
| Autistic Disorder | 1 | 2022 | 346 | 0.160 |
Why?
|
| Time Factors | 2 | 2021 | 6201 | 0.160 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 26 | 0.160 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2018 | 15 | 0.150 |
Why?
|
| Critical Care | 1 | 2024 | 650 | 0.150 |
Why?
|
| Leukopenia | 1 | 2018 | 44 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2022 | 470 | 0.150 |
Why?
|
| Brain | 3 | 2022 | 2947 | 0.140 |
Why?
|
| Interdisciplinary Studies | 1 | 2017 | 5 | 0.140 |
Why?
|
| Child Development | 1 | 2019 | 252 | 0.140 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 36 | 0.140 |
Why?
|
| Neutropenia | 1 | 2018 | 202 | 0.140 |
Why?
|
| Post-Concussion Syndrome | 1 | 2017 | 54 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2020 | 365 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 434 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 426 | 0.130 |
Why?
|
| Neural Pathways | 1 | 2017 | 264 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2023 | 15981 | 0.130 |
Why?
|
| Female | 13 | 2023 | 65432 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1872 | 0.120 |
Why?
|
| Age Factors | 1 | 2021 | 2801 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 958 | 0.110 |
Why?
|
| Language Development | 1 | 2013 | 31 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1306 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 921 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1418 | 0.110 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8089 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2013 | 190 | 0.100 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 367 | 0.100 |
Why?
|
| Retinal Telangiectasis | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2012 | 74 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5048 | 0.100 |
Why?
|
| Alexander Disease | 1 | 2011 | 2 | 0.100 |
Why?
|
| Walking | 1 | 2013 | 206 | 0.100 |
Why?
|
| Medulla Oblongata | 1 | 2011 | 22 | 0.100 |
Why?
|
| Telomere-Binding Proteins | 1 | 2012 | 47 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1011 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2017 | 4709 | 0.090 |
Why?
|
| Telomere | 1 | 2012 | 208 | 0.090 |
Why?
|
| Intellectual Disability | 1 | 2017 | 1043 | 0.090 |
Why?
|
| Hospitals | 2 | 2022 | 397 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 2048 | 0.080 |
Why?
|
| Length of Stay | 1 | 2013 | 1284 | 0.070 |
Why?
|
| Cerebellum | 1 | 2011 | 415 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2020 | 12103 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3332 | 0.070 |
Why?
|
| Seizures | 2 | 2022 | 871 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3260 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 965 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 1733 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1315 | 0.060 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 30 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 84 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 27 | 0.050 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2022 | 3 | 0.050 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2022 | 40 | 0.050 |
Why?
|
| Pancytopenia | 1 | 2022 | 40 | 0.050 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 30 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 104 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2022 | 98 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3098 | 0.050 |
Why?
|
| Paresthesia | 1 | 2020 | 7 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1114 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 171 | 0.040 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2020 | 13 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2020 | 83 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2020 | 107 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 612 | 0.040 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2017 | 12 | 0.040 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 42 | 0.040 |
Why?
|
| Aggression | 1 | 2019 | 226 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 131 | 0.040 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 105 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 104 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 188 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 253 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 780 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2019 | 379 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3548 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 4225 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1167 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1387 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 865 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3662 | 0.020 |
Why?
|
| Muscle Hypotonia | 1 | 2012 | 185 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1172 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 2943 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 804 | 0.020 |
Why?
|
| Histones | 1 | 2012 | 528 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 3093 | 0.020 |
Why?
|
| United States | 1 | 2022 | 10618 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3871 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 1760 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 33741 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 5778 | 0.010 |
Why?
|